Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Mansutti · SciRah

Researcher profile · Semantic Scholar

M. Mansutti

Share profile

M. Mansutti — researcher profile on SciRah

h-index: 25
Works: 129
Citations: 4,214

Most-cited papers

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas +16 more
2010The Lancet1,229 citations
Semantic Scholar
Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
L. Gianni, W. Eiermann, V. Semiglazov, A. Lluch +16 more
2014The Lancet Oncology467 citations
Semantic Scholar
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
M. Bonotto, L. Gerratana, E. Poletto, P. Driol +8 more
2014The Oncologist282 citations Open access
Semantic Scholar
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
L. Gianni, G. Romieu, M. Lichinitser, S. Serrano +13 more
2013Journal of Clinical Oncology246 citations
Semantic Scholar
Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
L. Gianni, J. Baselga, W. Eiermann, V. G. Porta +14 more
2009Journal of Clinical Oncology204 citations Open access
Semantic Scholar
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
L. Gianni, G. Bisagni, M. Colleoni, L. Del Mastro +7 more
2018The Lancet Oncology152 citations Open access
Semantic Scholar
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial
L. Gianni, M. Mansutti, A. Antón, L. Calvo +17 more
2018JAMA Oncology127 citations Open access
Semantic Scholar
Drug waste minimization as an effective strategy of cost-containment in Oncology
G. Fasola, G. Aprile, L. Marini, A. Follador +2 more
2014BMC Health Services Research74 citations Open access
Semantic Scholar
Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.
L. Del Mastro, M. Mansutti, G. Bisagni, R. Ponzone +24 more
2021The Lancet Oncology71 citations
Semantic Scholar
Drug waste minimisation and cost-containment in Medical Oncology: Two-year results of a feasibility study
G. Fasola, Marianna Aita, L. Marini, A. Follador +6 more
2008BMC Health Services Research67 citations Open access
Semantic Scholar
Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker
G. Pelizzari, D. Basile, S. Zago, C. Lisanti +13 more
2019Cancers58 citations Open access
Semantic Scholar
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis.
M. Bonotto, L. Gerratana, M. di Maio, C. de Angelis +12 more
2017Breast56 citations Open access
Semantic Scholar
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
M. Zambetti, M. Mansutti, P. Gómez, A. Lluch +11 more
2012Breast Cancer Research and Treatment51 citations
Semantic Scholar
Unplanned presentations of cancer outpatients: a retrospective cohort study
G. Aprile, Federica Edith Pisa, A. Follador, L. Foltran +6 more
2013Supportive Care in Cancer46 citations
Semantic Scholar
S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)
L. Gianni, G. Romieu, M. Lichinitser, S. Serrano +14 more
201146 citations
Semantic Scholar
Thymidine phosphorylase expression is associated with time to progression in patients receiving low-dose, docetaxel-modulated capecitabine for metastatic breast cancer.
F. Puglisi, G. Cardellino, D. Crivellari, C. di Loreto +9 more
2008Annals of Oncology43 citations Open access
Semantic Scholar
A multicentre Phase II study of non-pegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer.
M. Venturini, Claudia Bighin, F. Puglisi, N. Olmeo +10 more
2010Breast33 citations Open access
Semantic Scholar
First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
D. Basile, L. Gerratana, C. Corvaja, G. Pelizzari +14 more
2021Breast32 citations Open access
Semantic Scholar
Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
G. Lunardi, P. Piccioli, P. Bruzzi, Rosario Notaro +13 more
2012Breast Cancer Research and Treatment23 citations Open access
Semantic Scholar
Follow-up results of NOAH, a randomized phase III trial evaluating neoadjuvant chemotherapy with trastuzumab (CT+H) followed by adjuvant H versus CT alone, in patients with HER2-positive locally advanced breast cancer.
L. Gianni, W. Eiermann, V. Semiglazov, A. Manikhas +15 more
201322 citations
Semantic Scholar
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments
L. Del Mastro, A. Fabi, M. Mansutti, M. de Laurentiis +11 more
2013BMC Cancer21 citations Open access
Semantic Scholar
Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.
Giorgio Mustacchi, M. Mansutti, C. Sacco, S. Barni +4 more
2009Annals of Oncology21 citations Open access
Semantic Scholar
ETNA (Evaluating Treatment with Neoadjuvant Abraxane) randomized phase III study comparing neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) both followed by anthracycline regimens in women with HER2-negative high-risk breast cancer: A MICHELANGO study.
L. Gianni, M. Mansutti, A. Antón, L. Calvo +16 more
201616 citations
Semantic Scholar
Exploratory predictive and prognostic factors in advanced breast cancer treated with metronomic chemotherapy
M. Miscoria, F. Tonetto, L. Deroma, Piernicola Machin +9 more
2012Anti-Cancer Drugs15 citations
Semantic Scholar
Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy.
E. Ongaro, L. Gerratana, M. Cinausero, G. Pelizzari +10 more
2018Future Oncology14 citations
Semantic Scholar
Abstract LBO1-02: Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial
L. Gianni, E. Munzone, M. Mansutti, G. Bianchini +20 more
2024Cancer Research13 citations
Semantic Scholar
Benefit from letrozole as extended adjuvant therapy after sequential endocrine therapy: A randomized, phase III study of Gruppo Italiano Mammella (GIM).
L. Del Mastro, M. Mansutti, G. Bisagni, R. Ponzone +16 more
2019Journal of Clinical Oncology13 citations
Semantic Scholar
Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.
L. Gianni, M. Mansutti, A. Antón, Lourdes Calvo Martínez +15 more
2019Journal of Clinical Oncology10 citations
Semantic Scholar
Body mass index and circulating oestrone sulphate in women treated with adjuvant letrozole
V. Sini, G. Lunardi, M. Cirillo, M. Turazza +14 more
2014British Journal of Cancer10 citations Open access
Semantic Scholar
Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?
L. Bortot, G. Targato, C. Noto, M. Giavarra +15 more
2022Frontiers in Oncology9 citations Open access
Semantic Scholar
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First‐Line Exemestane: Results From a Prospective Study
S. Gagno, M. D'Andrea, M. Mansutti, Chiara Zanusso +36 more
2019Clinical Breast Cancer8 citations Open access
Semantic Scholar
Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
C. Bozza, C. Fontanella, V. Buoro, M. Mansutti +1 more
2015Expert Review of Clinical Pharmacology8 citations
Semantic Scholar
A37Metastatic breast cancer and circulating exosomes. Hints from an exploratory analysis
L. Gerratana, B. Toffoletto, Michela Bulfoni, D. Cesselli +11 more
20158 citations Open access
Semantic Scholar
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials
E. Blondeaux, Wan-Ling Xie, L. Carmisciano, S. Mura +21 more
2024EClinicalMedicine7 citations Open access
Semantic Scholar
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) survey.
M. Bonotto, D. Basile, L. Gerratana, G. Pelizzari +11 more
2018Breast7 citations
Semantic Scholar
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials
B. Conte, L. Boni, G. Bisagni, A. Durando +31 more
2023Clinical Cancer Research5 citations Open access
Semantic Scholar
Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.
L. Gianni, M. Colleoni, G. Bisagni, M. Mansutti +7 more
2019Journal of Clinical Oncology5 citations
Semantic Scholar
Abstract P4-21-39: Neo-adjuvant treatment with trastuzumab and pertuzumab associated with palbociclib and fulvestrant in HER2-positive and ER-positive breast cancer: Effect on Ki67 during and after treatment. A phase II Michelangelo study
L. Gianni, G. Bisagni, M. Colleoni, L. Del Mastro +7 more
20175 citations
Semantic Scholar
Use of pegfilgrastim support on day 9 to maintain relative dose intensity of chemotherapy in breast cancer patients receiving a day 1 and 8 CMF regimen
R. Mattioli, C. Gridelli, J. Castellanos, A. Duque +10 more
2009Clinical and Translational Oncology5 citations
Semantic Scholar
Modulation by treatment of tumor infiltrating lymphocytes (TILs) and PDL1 expression in triple-negative breast cancer in the ETNA trial.
G. Bianchini, C. Smart, M. Mansutti, H. Lück +16 more
20204 citations
Semantic Scholar
Clinico-radiological monitoring strategies in patients with metastatic breast cancer: a real-world study.
M. Bonotto, D. Basile, L. Gerratana, M. Bartoletti +11 more
2020Future Oncology4 citations
Semantic Scholar
Prognostic role of alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) in metastatic breast cancer (MBC) patients: First clues for cost-effective biomarkers.
G. Pelizzari, L. Gerratana, D. Basile, M. Vitale +16 more
20184 citations
Semantic Scholar
Biomarker (BM) Results from the Phase III Averel Trial of 1st-Line Bevacizumab (BV), Trastuzumab (H) + Docetaxel (T) for HER2-Positive Locally Recurrent/Metastatic Breast Cancer (LR/MBC)
L. Gianni, A. Chan, M. Mansutti, X. Pivot +6 more
20124 citations Open access
Semantic Scholar
CDK4/6 Inhibitors as Upfront Treatment in a Patient with Breast Cancer Presenting with a Clinical Critic Situation: A Case Report and Review of the Literature
G. Targato, L. Bortot, Arianna Dri, M. Bonotto +3 more
2022Current Oncology3 citations Open access
Semantic Scholar
Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the ECTO trial.
G. Bianchini, V. Cappelletti, M. Callari, M. Carcangiu +16 more
20133 citations
Semantic Scholar
Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC)
M. Mansutti, G. Cavazzini, V. Lorusso, C. Boni +4 more
20083 citations
Semantic Scholar
Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment.
L. Del Mastro, A. Fabi, M. Mansutti, M. de Laurentiis +14 more
20122 citations
Semantic Scholar
The impact of COVID-19 pandemic on oncology workload: The experience of an Italian Reference Cancer Center.
Carla Corvaja, G. Targato, S. Garattini, C. Barazzutti +7 more
2021Journal of Clinical Oncology1 citations
Semantic Scholar
Abstract P3-11-07: A randomized phase II trial of reparixin, a CXCR1 inhibitor, in combination with paclitaxel in the treatment of mTNBC
L. Goldstein, M. Mansutti, C. Lévy, Jenny C. Chang +9 more
2020Poster Session Abstracts1 citations
Semantic Scholar
What to do in an oncology department to face the new COVID-19 era challenges?
S. Garattini, A. Bin, R. Donato, M. Mansutti +5 more
2020Medical Oncology1 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Puglisi×19
Invite
F. Puglisi — researcher profile on SciRah
G. Fasola×16
Invite
G. Fasola — researcher profile on SciRah
L. Del Mastro×15
Invite
L. Del Mastro — researcher profile on SciRah
L. Gianni×14
Invite
L. Gianni — researcher profile on SciRah

×14

Invite

P. Valagussa — researcher profile on SciRah

A. Minisini×13

Invite

A. Minisini — researcher profile on SciRah

Invite

G. Bisagni — researcher profile on SciRah

M. Zambetti×11

Invite

M. Zambetti — researcher profile on SciRah

Invite

M. Bonotto — researcher profile on SciRah

L. Gerratana×9

Invite

L. Gerratana — researcher profile on SciRah

V. Semiglazov×8

Invite

V. Semiglazov — researcher profile on SciRah

Invite

S. Russo — researcher profile on SciRah